Tag - ANAB

Developments

Vanda and Anaptys ink licencing agreement for commercialization of imsidolimab in GPP

Vanda Pharmaceuticals (NASDAQ:VNDA) and AnaptysBio (NASDAQ: ANAB) have announced an exclusive global licencing agreement granting Vanda the rights to commercialize imsidolimab, a treatment for generalized pustular...

February 3, 2025

Developments

AnaptysBio reports positive topline data from Phase 2 pustular psoriasis trial

AnaptysBio (NASDAQ:ANAB) reported positive topline data from an interim analysis of its Phase 2 trial evaluating imsidolimab or the treatment of generalized pustular psoriasis (GPP). GPP is a rare, chronic, life...

October 13, 2020

Developments

AnaptysBio imsidolimab gets FDA orphan drug designation for pustular psoriasis

The FDA granted AnaptysBio’s (NASDAQ:ANAB) imsidolimab orphan drug designation for the treatment of generalized pustular psoriasis (GPP). GPP is a rare, chronic, life-threatening disease characterized by the development...

July 8, 2020

Developments

AnaptysBio presents updated Phase 2a data of etokimab in asthma

AnaptysBio (NASDAQ:ANAB) presented updated Phase 2a data of etokimab for the treatment of severe eosinophilic asthma at the European Academy of Allergy and Clinical Immunology congress. Etokimab is a humanized anti...

June 5, 2019

Tag - ANAB

Vanda and Anaptys ink licencing agreement for commercialization of imsidolimab in GPP

AnaptysBio reports positive topline data from Phase 2 pustular psoriasis trial

AnaptysBio imsidolimab gets FDA orphan drug designation for pustular psoriasis

AnaptysBio presents updated Phase 2a data of etokimab in asthma

Subscribe